Research Luxembourg and French Biotech company partner to help drive innovation in cancer immunotherapy
21 October 2021
Cancer immunotherapy based on immune checkpoint blockade has provided significant clinical benefits in many cancers. Despite the encouraging and promising clinical responses observed in a few patients, the majority have only a short-term survival benefit, if any, and severe side effects.
There is a clinical urge to design combinatorial strategies to extend the benefits of immunotherapy to a large number of cancer patients.
The Luxembourg Institute of Health partnered with French Biotech company Advanced BioDesign to develop novel approaches that effectively extend the benefit of cancer immunotherapy. This collaboration aims to potentiate the effectiveness of immunotherapy and provide a revolutionary approach to treating cancers.
Combing innovative and highly selective molecules inhibiting resistance mechanisms in multiple cancers
This collaboration is bringing about ” TRICK-ALDH “. In this project, scientists will evaluate the benefits of immunotherapy combined with premium oncology drugs to effectively suppress carcinogenesis and prevent resistance to cancer therapies.
The overall objective of the TRICK-ALDH project is to provide a new, rational combination of targeted therapy and immunotherapy to achieve long-term survival benefit for solid tumours, with a particular focus on melanoma and lung cancer.
As a result of this collaboration between Research Luxembourg’s scientists and Advanced BioDesign, the teams hope to develop innovative immunotherapeutic combination approaches that could generate considerable momentum in the field of cancer care.
Making the most of the scientific and business expertise
Building bridges between science and the industry is a priority for Luxembourg. The TRICK-ALDH project is a prime example of this commitment to stimulate partnerships between public research institutes and companies as it received financial support from the Luxembourg National Research Fund under the BRIDGES scheme. This programme aims to provide financial support for industry partnerships between public research institutions in Luxembourg and national or international companies.
We believe that true translational oncology and translational research in general can only effectively be achieved by leveraging the scientific and business expertise of internationally renowned industrial partners. We are confident that our close collaboration with Advanced BioDesign will catalyse the development of the next-generation of combinatorial treatments for a variety of cancers, with concrete and tangible benefits in the clinical practice.Dr Bassam Janji, Head of Tumor Immunotherapy and Microenvironment group, Luxembourg Institute of Health
More about this partnership.
Unlocking breakthroughs: Japan-Luxembourg collaboration unveils key discoveries for diagnosing neurodegenerative diseasesAn international team consisting of researchers from Japan and Luxembourg show for the first time that pathological forms of the…
Prof. Tkatchenko receives an ERC grant for drug development with AIThe physicist Prof. Alexandre Tkatchenko of the University of Luxembourg, has received a “Proof of Concept” Grant from the European…
SciLux podcast – Sophie Pilleron, cancer epidemiologistDr Sophie Pilleron is a cancer epidemiologist at the Luxembourg Institute of Health (LIH), head of the interdisciplinary ACADI team,…
10 selected Research Luxembourg results – March 2023Aelyn Chong Castro, Flickr, Pixabay, Craiyon AI Luxembourg students send five ‘mini brains’ to the ISS Luxembourg Centre for Systems…
SciLux podcast – Stefano Pozzi Mucelli, European RDI support & Alberto Noronha, CEO of NIUMFormer PhD student and research associate at the University of Luxembourg, Alberto Noronha is the co-funder and CEO of NIUM…
Research Luxembourg COVID-19 Task Force awarded the 2022 Science for Society PrizeThe 2022 Science for Society Prize, an initiative of the Science for Society Foundation, under the aegis of Fondation de…
SciLux podcast – Markus Ollert, Infection & Immunity Department directorProfessor Markus Ollert is the Director of the Infection and Immunity Department of the Luxembourg Institute of Health (LIH). He…
Shifts in human gut microbiome due to COVID-19COVID-19, caused by an infection with the SARS-CoV-2 virus, was declared a global pandemic by the World Health Organisation (WHO)…